We found an increased MKK7 and JNK activation in liver tissues from NAFLD mice, which was remarkably reduced by anti-TNFR1 but not by control-Ab treatment (Fig. 5a). Here, MAP2K7 is linked to metabolic dysfunction-associated steatotic liver disease.